CELESTODERM V OINTMENT

Country: Կանադա

language: անգլերեն

source: Health Canada

buyitnow

SPC SPC (SPC)
29-09-2020

active_ingredient:

BETAMETHASONE (BETAMETHASONE VALERATE)

MAH:

BAUSCH HEALTH, CANADA INC.

ATC_code:

D07AC01

INN:

BETAMETHASONE

dosage:

0.1%

pharmaceutical_form:

OINTMENT

composition:

BETAMETHASONE (BETAMETHASONE VALERATE) 0.1%

administration_route:

TOPICAL

units_in_package:

450G

prescription_type:

Prescription

therapeutic_area:

ANTI-INFLAMMATORY AGENTS

leaflet_short:

Active ingredient group (AIG) number: 0106299001; AHFS:

authorization_status:

APPROVED

authorization_date:

2014-10-10

SPC

                                PRESCRIBING INFORMATION
PR
CELESTODERM
® V
Betamethasone valerate cream USP
Betamethasone valerate ointment USP
0.1%
PR
CELESTODERM
® V/2
Betamethasone valerate cream USP
Betamethasone valerate ointment USP
0.05%
TOPICAL CORTICOSTEROID
September
29
,
2020
DATE OF
REVISION:
Control
#:
242776
H7L 4A8
Laval, Quebec
2150 St-Elzear
Blvd. West
,
BAUSCH HEALTH, CANADA INC.
_ _
_Pr_
_CELESTODERM _
_®_
_ V and CELESTODERM_
_®_
_ V/2 Prescribing Information Page 2 of 10_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS…………………………………………………......4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
..................................................................................................................9
ACTION AND CLINICAL PHARMACOLOGY
..............................................................9
STORAGE AND STABILITY
............................................................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................9
_ _
_Pr_
_CELESTODERM _
_®_
_ V and CELESTODERM_
_®_
_ V/2 Prescribing Information Page 3 of 10_ PR
CELESTODERM
® V
Betamethasone valerate cream USP
Betamethasone valerate ointment USP
0.1%
PR
CELESTODERM
® V/2
Betamethasone valerate cream USP
Betamethasone val
                                
                                read_full_document
                                
                            

documents_in_other_languages

SPC SPC ֆրանսերեն 29-09-2020